Paul Celano, MD
Medical Oncology · Baltimore, MDNPI 1649222845
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by GSK at 34.3% of the total. That places this record below the midpoint for medical oncology clinicians in MD, where the typical reported total is $4,199.
Across 113 payments — averaging $51.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Bayer$963
- AstraZeneca$283
- E.r. Squibb & Sons, L.L.C.$234
- Gilead$211
- Astellas Pharma US Inc$210
- plus $2K from 33 others
Across 356 payments — averaging $3058.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$708K
- AstraZeneca$163K
- Genentech, Inc.$114K
- Clovis Oncology, Inc.$37K
- Astrazeneca UK Limited$32K
- Pfizer$16K
- plus $19K from 2 others
What the payments were for
- Consulting fees$2,85049%
- Food & beverage$2,68146%
- Education$2695%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 3 | $1,988 |
| Bayer | 3 | $963 |
| AstraZeneca | 8 | $283 |
| E.r. Squibb & Sons, L.L.C. | 8 | $234 |
| Gilead | 4 | $211 |
| Astellas Pharma US Inc | 7 | $210 |
| Daiichi Sankyo Inc. | 8 | $192 |
| Merck | 8 | $159 |
| AbbVie | 6 | $151 |
| Johnson & Johnson | 6 | $151 |
| Novartis | 5 | $130 |
| Bristol Myers Squibb | 4 | $112 |
| Exelixis Inc. | 4 | $107 |
| AVEO Pharmaceuticals, Inc. | 2 | $105 |
| Pfizer | 4 | $102 |
| Regeneron Healthcare Solutions, Inc. | 3 | $87 |
| Seagen Inc. | 4 | $59 |
| Genentech USA, Inc. | 3 | $54 |
| Sanofi | 2 | $47 |
| Array Biopharma Inc | 2 | $45 |
| Janssen Scientific Affairs, LLC | 1 | $30 |
| Mirati Therapeutics, Inc. | 1 | $29 |
| Geron Corporation | 1 | $29 |
| Pharmacosmos Therapeutics Inc. | 1 | $27 |
| Pharmaand GmbH | 1 | $27 |
| Tolmar, Inc. | 1 | $27 |
| Beone Medicines USA, Inc. | 1 | $26 |
| Sandoz | 1 | $25 |
| Incyte Corporation | 1 | $25 |
| Eisai Inc. | 1 | $22 |
| Caris MPI, Inc. | 1 | $21 |
| Deciphera Pharmaceuticals Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $16 |
| Vertex | 1 | $15 |
| Aurobindo Pharma USA, Inc. | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $15 |
| Clovis Oncology, Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,800 in reported general payments places this provider in the 50th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 27 | $412,511 |
| CabometyxCabozantinib S-Malate | 15 | $401,742 |
| CalquenceAcalabrutinib Maleate | 20 | $212,187 |
| XtandiEnzalutamide | 14 | $181,449 |
| NubeqaDarolutamide | 13 | $174,633 |
| Imatinib Mesylate | 13 | $61,059 |
| Abiraterone Acetate | 20 | $9,881 |
| EliquisApixaban | 11 | $8,321 |
| Exemestane | 23 | $1,967 |
| Dexamethasone | 39 | $1,754 |
| Anastrozole | 39 | $663 |
| Prochlorperazine Maleate | 59 | $578 |
| Oxycodone Hcl | 24 | $575 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 19 | $429 |
| Gabapentin | 22 | $312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $107 | $401,74215 claims |
| AstraZenecaCalquence | $283 | $212,18720 claims |
| Astellas Pharma US IncXtandi | $210 | $181,44914 claims |
| BayerNubeqa | $963 | $174,63313 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $30 | $9,88120 claims |
| PfizerEliquis | $102 | $8,32111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 180 medical oncology providers in Maryland.
Other medical oncology in Baltimore
- Mario EisenbergerBaltimore$2.9M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
- Evan LipsonBaltimore$228K
- Nilofer AzadBaltimore$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.